On Nov 12, 2025, PHGE reported earnings of -5.51 USD per share (EPS) for Q3 25, beating the estimate of -6.20 USD, resulting in a 11.15% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -1.88% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 4 analysts forecast an EPS of -4.70 USD, with revenue projected to reach -- USD, implying an decrease of -14.70% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Abbott Laboratories
Report Date
Jan 22, 2026 For Q4 25
Estimate
$1.51
Actual
$1.50
Surprise
-0.75%
Stryker Corporation
Report Date
Jan 29, 2026 For Q4 25
Estimate
$4.43
Actual
$4.47
Surprise
+0.69%
ResMed Inc.
Report Date
Jan 29, 2026 For Q2 26
Estimate
$2.75
Actual
$2.81
Surprise
+2.15%
High Tide Inc. Common Shares
Report Date
Jan 29, 2026 For Q4 25
Estimate
$0.00
Actual
$0.01
Surprise
0.00%
FAQ
What were BiomX Inc.'s earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, BiomX Inc. reported EPS of -$5.51, beating estimates by 11.15%, and revenue of $0.00, 0% as expectations.
How did the market react to BiomX Inc.'s Q3 2025 earnings?
The stock price moved down -1.88%, changed from $7.29 before the earnings release to $7.15 the day after.
When is BiomX Inc. expected to report next?
The next earning report is scheduled for Mar 23, 2026.
What are the forecasts for BiomX Inc.'s next earnings report?
Based on 4
analysts, BiomX Inc. is expected to report EPS of -$4.70 and revenue of -- for Q4 2025.